Latest News

FDA OKs New Treatment for Hemophilia A
Turoctocog alfa pegol, also known as N8-GP (Esperoct, Novo Nordisk), is indicated for adults and children with hemophilia A.
Pembrolizumab (Keytruda, Merck) is the first anti-PD-1 therapy approved in the adjuvant setting across patients with stage 3 melanoma.
Pembrolizumab (Keytruda) plus axitinib (Inlyta) was evaluated in a clinical trial of patients with clear-cell metastatic renal cell carcinoma.
Blocking the interaction between interleukin-33 and regulatory T cells may serve as a new therapeutic target for cancers associated with chronic inflammatory diseases.
Top news of the day across the health care landscape.
MDNA55 prolonged survival in IL4R-positive patients with recurrent glioblastoma in a phase 2b clinical trial.
Prevalence of cognitive impairment has increased among the HIV population while services for diagnosing and treating afflicted individuals remains scarce.
The sBLA is based on data showing significant improvement in overall survival and progression-free survival in patients with advanced renal cell carcinoma.


How Can We Advance Progress in Moving From Volume to Value in Health Care?
It is critical that we continue to recognize that better health outcomes are a critically important corollary to value.
There is no doubt that 2018 was a year of transformation across the health care spectrum, and specialty pharmacy was no exception.
For a current compounder or someone looking to enter the space, it is imperative that their business remains on top of the latest compounding developments.
Unfortunately, there is no way to stop a category 5 hurricane, but it doesn’t have to result in catastrophe for patients.

Featured Company Profile

MHA Specialty Pharmacy Solutions: Patient Engagement Strategies for Your Pharmacy


Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the need for increased pharmacy benefit manager regulation on a federal level.

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, discusses how a multi-disciplinary clinic model improves patient care in hemophilia treatment centers.

Current Issue

Volume: 10
Number: 1

Most Popular

Previous TabNext Tab
Strategic Alliance Partners
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.